Sophia Genetics's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 58.79.
Sophia Genetics's Days Inventory for the
three
months ended in Mar. 2026 was 88.35.
Sophia Genetics's Days Payable for the
three
months ended in Mar. 2026 was 118.24.
Therefore, Sophia Genetics's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 28.90.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Sophia Genetics Cash Conversion Cycle Related Terms
Sophia Genetics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOPH vs WEAV, NRC, MDRX: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, Sophia Genetics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Sophia Genetics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a Cash Conversion Cycle of 28.90 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sophia Genetics and its competitors.
Is Sophia Genetics' Cash Conversion Cycle too high?
Sophia Genetics' current Cash Conversion Cycle is 28.90. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.21. Sophia Genetics' value of 28.90 is 58.7% above this industry median. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Cash Conversion Cycle compare to WEAV and NRC?
Sophia Genetics' Cash Conversion Cycle of 28.90 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.21. Sophia Genetics' value of 28.90 is 58.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current Cash Conversion Cycle of 28.90 is 58.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Cash Conversion Cycle is 28.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.03, compared to a current price of $5.75 — trading 14.3% above its estimated fair value. The current Cash Conversion Cycle is 28.90 and 58.7% above the Healthcare Providers & Services industry median of 18.21. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Cash Conversion Cycle is 28.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $5.75 is trading 14.3% above its estimated GF Value™ of $5.03.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for SOPH:
Cash Conversion Cycle: 28.90
GF Value™: $5.03 vs. price of $5.75 (14.3% above fair value)
Industry Position: 58.7% above the Healthcare Providers & Services median
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score
Get the complete analysis for SOPH
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
